Amerikanische Gesellschaft für Hirudotherapie

The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes

Research article published in Seminars in vascular medicine (2003)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungHaas S et al. · Seminars in vascular medicine, 2003

Abstract

Due to their favorable pharmacologic properties and beneficial clinical effects, low molecular weight heparins (LMWHs) have become the standard of care in the prevention and treatment of venous thromboembolism and have also been extensively studied in the treatment of acute coronary syndromes. Pentasaccharide is the first of a new class of synthetic antithrombotics and has been shown to be superior to LMWH in preventing deep vein thrombosis. Hirudin is the most potent direct thrombin inhibitor and has provided superior antithrombotic efficacy when compared with LMWH. In acute coronary syndromes, however, the antithrombotic activity of hirudin has been compromised by a significant increase in major hemorrhage.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAngina, UnstableAnticoagulantsClinical Trials as TopicFibrinolytic AgentsFondaparinuxHeparinHeparin, Low-Molecular-WeightHirudin TherapyHumansMyocardial InfarctionPolysaccharidesVenous Thrombosis

Zusammenfassung

The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.

Warum dies für die Hirudotherapie relevant ist

This article reviews the clinical roles of low molecular weight heparins (LMWHs), the synthetic pentasaccharide, and hirudin in managing venous thromboembolism and acute coronary syndromes. The abstract highlights that hirudin is the most potent direct thrombin inhibitor and demonstrated superior antithrombotic efficacy relative to LMWH, though in acute coronary settings this benefit was offset by a significant increase in major hemorrhage. For ASH's research domain, the article is relevant for its direct discussion of hirudin as an anticoagulant in clinical use, weighing its therapeutic advantages against its bleeding risks. However, this review synthesizes broader clinical trial literature; it offers no new primary data and does not address live hirudotherapy, hirudin's biological origins, or the wider leech secretome.

Zitation

The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes

Haas S et al. · Seminars in vascular medicine, 2003

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.